SVB Leerink Downgrades Moderna (MRNA) to Underperform

SVB Leerink analyst Mani Foroohar downgraded Moderna (NASDAQ: MRNA) from Market Perform to Underperform with a price target of $93.00 (from $111.00).

For an analyst ratings summary and ratings history on Moderna click here. For more ratings news on Moderna click here.

Shares of Moderna closed at $147.57 yesterday.

You May Also Be Interested In

• Macquarie Downgrades Mercari, Inc (4385:JP) (MRCIF) to Neutral
• Opus Genetics (IRD) PT Raised to $13 at Wedbush
• J. Front Retailing Co., Ltd (3086:JP) (JFROF) PT Raised to JPY2,440 at Nomura/Instinet